[rory]

By chance I just talked to someone with deeper knowledge on this and they said the current constraint is actually ramping up supply of the delivery mechanism, not the drug.

I have zero expertise on this, but would be curious if anyone knows what's special about Ozempic delivery that can't be served by a commodity syringe.

[jaggederest]

> but would be curious if anyone knows what's special about Ozempic delivery that can't be served by a commodity syringe.

They can't charge as much. That's basically it. Generic semaglutide from compounding pharmacies (which have their own issues for sure) is under $150 a month cash-pay these days.

The real issue with syringes and self administration is that the vast majority of the population are not comfortable with it and don't have the diligence to do it correctly every time, so you get under/over dosage or noncompliance.

That being said, the autoinjector format doesn't really solve that problem, it just slightly ameliorates it, in exchange for approximately 8x the cost.

[kurthr]

So basically, 99.8% margin the maximum they can charge (at ~15-30cents/mo) or 99.5% margin at $1000/mo for a $2.5 injector? Semaglutide has been in production since 2012 and approved by the FDA since 2017. There's a real chance that specifically as a weight loss drug it's not patentable since it was in off label use before the patent was filed. That's being argued in the PTO now.

[zahlman]

>Generic semaglutide from compounding pharmacies (which have their own issues for sure) is under $150 a month cash-pay these days.

...Is that supposed to be impressive? I assume you mean USD, so that works out to more than I pay for my food. Toronto isn't a cheap place to buy food, either.

[cubefox]

> By chance I just talked to someone with deeper knowledge on this and they said the current constraint is actually ramping up supply of the delivery mechanism, not the drug.

The article says this:

> Surprisingly, the study found that the biggest cost in producing Ozempic is not the active medicine, called semaglutide, but the disposable pens used to inject it. They can be made for no more than $2.83 per month’s supply, the authors concluded, based on interviews with former employees and consultants to injection device manufacturers. One Ozempic pen is used weekly and lasts a month.

So while the injection pens are significantly more expensive than manufacturing the drug itself, they are still relatively cheap. So it seems to be not a major problem to strongly ramp up production here as well.

Which suggests any supply shortage will be resolved relatively quickly. Perhaps in less than a year? Then the limiting factor will not be the supply but the market price.

[CydeWeys]

There are also doctors that are prescribing vials of semaglutide and commodity needles, and training patients to properly dose up and administer the drug via a standard needle. There's more to it than the auto-injector pens, but not that much more to it. And it does bring costs down, which is important to some. Alternatively, you can just go to the doctor's office weekly and have a nurse there do a traditional injection for you (doesn't help as much with costs, but does bypass the auto-injector shortage).

[op00to]

> what's special about Ozempic delivery

People don't want to use a commodity syringe. People are scared of needles. The autoinjectors take most of the fear out of it.

[courseofaction]

Teach a man to fish, and you can't charge him obscene amounts for fishing to be done for him.

[davio]

hims sells the generic version for a fraction of the price but you have to do regular injections

[Someone1234]

"hims" is selling Compound Pharmacy drugs, which will be made illegal soon. Soon your options will be $1000-1500/month from the two big drug companies.

They're meant to have a vial-needle version, but it is $600/month and you can only do it for up to 5-months and a low max dose. So it isn't a real program, but rather a way to avoid critique from legislators.